Physician profile
Christopher J Engelman
NPI 1093778326
$12,819.01
in general payments reported to CMS, 2019-2025
18 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $1,016 · 2021: $8,988 · 2022: $575 · 2023: $348 · 2024: $231 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,849.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $9,601.20 | 2019-2021 | |
| Abbvie INC. | $1,049.99 | 2022-2025 | |
| Allergan, INC. | $283.50 | 2019-2021 | |
| Alcon Vision LLC | $275.73 | 2019-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| Tarsus Pharmaceuticals, INC. | $273.22 | 2025 | Xdemvy |
| Thea Pharma INC. | $246.22 | 2023-2025 | Iyuzeh |
| Rxsight INC | $173.84 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Glaukos Corporation | $159.77 | 2022-2025 | Idosetr, Idose |
| Sight Sciences, INC. | $137.55 | 2021-2024 | Tearcare System, Omni Surgical System |
| Bausch & Lomb Americas INC. | $114.69 | 2022-2025 | Vyzulta, Miebo |
| Carl Zeiss Meditec, INC. | $111.89 | 2019 | |
| Sun Pharmaceutical Industries INC. | $93.57 | 2022-2025 | Xelpros, Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $71.25 | 2020-2021 | |
| Akorn Operating Company LLC | $64.48 | 2021 | |
| Biotissue Holdings INC. | $55.02 | 2019-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $54.53 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $36.46 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $16.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Engelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.